Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 83

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 83
---
<div align='center'>15</div>

TABLE OF CONTENTS

growth and to align the economic interests of such persons with those of its stockholders. The summary of the Incentive Plan above is qualified in its entirety by reference to the complete text of the Incentive Plan, a copy of which is attached as Annex B to this proxy statement/prospectus. You are encouraged to read the Incentive Plan in its entirety. See the section entitled “Proposal No. 3 — The Incentive Plan Proposal. ”

#### The ParentCo Charter Proposal
At the closing, ParentCo will adopt the ParentCo Certificate of Incorporation in the form set forth in Annex C . Assuming the Business Combination Proposal is approved, Iris’s stockholders are also being asked to approve, on a non-binding advisory basis, the material differences between the Iris Certificate of Incorporation and the ParentCo Certificate of Incorporation that will be effective upon the closing. See the section entitled “Proposal No. 4 — The ParentCo Charter Proposal. ”

#### Advisory Charter Proposals
Assuming the Business Combination Proposal and other Required Proposals are approved, Iris stockholders are also being asked to approve, on a non-binding advisory basis, the Advisory Charter Proposals in connection with the replacement of the Iris Certificate of Incorporation with the Proposed ParentCo Certificate of Incorporation under the DGCL. In accordance with SEC guidance, this proposal is being presented separately and will be voted upon on a non-binding advisory basis and is being presented as six separate sub-proposals, as follows:

(1)

Advisory Charter Proposal A — to amend the name of the public entity to “Liminatus Pharma, Inc.” from “Iris Acquisition Corp”;

(2)

Advisory Charter Proposal B — to authorize the issuance of up to 500,000,000 shares of common stock, and up to 1,000,000 shares of “blank check” preferred stock, the rights, preferences and privileges of which may be designated from time to time by Liminatus’s board of directors;

(3)

Advisory Charter Proposal C — to provide that the removal of any director be only for cause and by the affirmative vote of at least 66 2 ∕ 3 % of Liminatus’s then-outstanding shares of capital stock entitled to vote generally in the election of directors;

(4)

Advisory Charter Proposal D — to make Liminatus’s corporate existence perpetual as opposed to Iris’s corporate existence, which is required to